All the Active Ingredient Drugs
UPLIZNA
Amgen
UPLIZNA
Anti-CD19. Inebilizumab 100 mg/10 ml. VIAL 3X10 ml. Concentr. for sol. for infus.
Initial doses: 300 mg (3 vials of 100 mg) IV infus. followed 2 weeks later by a sec. 300 mg IV infus.
Maint. doses: 300 mg every 6 months. Inebilizumab is for chron. tmt.
Monother. for adlts with neuromyelitis optica spectrum disorders (NMOSD) who are anti-aquaporin-4 immunoglobulin G (AQP4-IgG) seropositive
C/I: Hypersens. • Sev. act. infect., incl. act. chron. infect. such as hepat. B
• Act. or untreat. latent TB.• Hist. of progr. multifocal leukoencephalopathy (PML)
• Sev. immunocomprom. state• Act. malign.
